ArticleInternational journal of clinical and experimental pathology2017
UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/β-catenin signaling pathway.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Unraveling the Role of Ubiquitin-Conjugating Enzyme UBE2T in Tumorigenesis: A Comprehensive Review.Cells · 2024Review
- A Hybrid CNN-Transformer Model for Predicting N Staging and Survival in Non-Small Cell Lung Cancer Patients Based on CT-Scan.Tomography (Ann Arbor, Mich.) · 2024Article
- Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.Journal of translational medicine · 2024Review
- Diverse roles of UBE2T in cancer (Review).Oncology reports · 2023Article
- Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.Biology · 2022Article
- Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis.World journal of hepatology · 2022Article
- Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5).Bioengineered · 2022Article
- UBE2T promotes β-catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation.Molecular oncology · 2022Article
- UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.Cell cycle (Georgetown, Tex.) · 2022Article
- Screening and Validation of Significant Genes with Poor Prognosis in Pathologic Stage-I Lung Adenocarcinoma.Journal of oncology · 2022Article
- NEDD4L-induced ubiquitination mediating UBE2T degradation inhibits progression of lung adenocarcinoma via PI3K-AKT signaling.Cancer cell international · 2021Article
- Review
- The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy.International journal of molecular sciences · 2021Review
- LncRNA CASC11 Promotes Hepatocellular Carcinoma ProgressionFrontiers in oncology · 2021Article
- Ubiquitin-conjugating enzyme E2T promotes tumor stem cell characteristics and migration of cervical cancer cells by regulating the GRP78/FAK pathway.Open life sciences · 2021Article
- Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUBE2T, a human E2 ubiquitin-conjugating enzyme, is overexpressed in some human cancers, suggesting the biological significance of UBE2T in cancer progression. However, its role in non-small cell lung cancer (NSCLC) progression is still unclear. This study was aimed to investigate the critical roles of UBE2T in NSCLC progression.
methodsQRT-PCR and Western blot were performed to explore the expression levels of UBE2T in NSCLC tissues and cell lines. Cell proliferation was detected using MTT assay and EdU assay. Cell invasion and migration were evaluated using transwell assay.
resultsOur data showed that UBE2T expression was upregulated in NSCLC tissues and cell lines. Functionally, UBE2T knockdown suppressed NSCLC cell proliferation, migration and invasion in vitro. Mechanistic investigations revealed that UBE2T downregulation suppressed the activity of Wnt/β-catenin signaling pathway.
conclusionThese results suggested that UBE2T play critical roles in the progression of NSCLC and could be a potential therapeutic target for the treatment of NSCLC patients.
Indexed as
Identifiers
31966822PMC6965922W3026987177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.